4259 |
Twice Broken Considered Sold |
Ganapathi Palaniappan |
Apr. 08. 22 |
4258 |
One of My Most Memorable Teaching CTO Cases |
Rosli Mohd Ali |
Apr. 08. 22 |
4257 |
TEER in Intermediate Risk Primary MR, Will It Follow the TAVR's Footsteps? |
Saibal Kar |
Apr. 08. 22 |
4256 |
TAVR for Asymptomatic Patients |
Phillippe Genereux |
Apr. 08. 22 |
4255 |
Leaflet Thrombosis, Is It Clinically Relevant? |
Duk-Woo Park |
Apr. 08. 22 |
4254 |
Long-Term Antithrombotic Strategy in PCI and AF Patients: Insights From the AFIRE Trial |
Satoshi Yasuda |
Apr. 08. 22 |
4253 |
DAPT Duration and NOAC Selection in the Afib-PCI Patient |
Renato D. Lopes |
Apr. 08. 22 |
4252 |
DAPT Study vs. Contemporary Trials: How Can We Reduce the Knowledge Gap? |
Robert W. Yeh |
Apr. 08. 22 |
4251 |
Optimal Antithrombotic Therapy After PCI in Asia (Japan): Why We Are Going Our Own Way? |
Takeshi Kimura |
Apr. 08. 22 |
4250 |
Role of CABG in Multivessel Disease |
Jack H. Boyd |
Apr. 08. 22 |